Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China

PHASE3CompletedINTERVENTIONAL
Enrollment

298

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Influenza A Virus InfectionInfluenza B Virus Infection
Interventions
DRUG

Zanamivir

10 mg inhaled by mouth, twice daily, for 5 days

DRUG

Placebo

inhaled by mouth, twice daily, for 5 days

Trial Locations (12)

Unknown

The Third Xiangya Hospital Of Central South University, Changsha

West China Hospital, Sichuan University, Chengdu

The First People's Hospital of Hangzhou, Hangzhou

The Affiliated Hospital of Inner Mongolia Medical College, Hohhot

The First Affiliated Hospital of Nanchang University, Nanchang

The First Affiliated Hospital of Nanjing Medical University, Nanjing

Qingdao Municipal Hospital, Qingdao

Shanghai 6th People's Hospital, Shanghai

Shanghai Changzheng Hospital, Shanghai

ShengJing Hospital of China Medical University, Shenyang

Tangdu Hospital Affiliated to the Fourth Military Medical University, Xi'an

Northern Jiangsu People's Hospital, Yangzhou

All Listed Sponsors
lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY